24 Rue du Faubourg St. Jacques
Faculty of Medicine René Descartes
Aterovax SA
Current treatments for atherosclerosis use markers and therapeutic targets that are consequences of the disease. Aterovax SA is attempting a more direct route. By basing its research and pipeline on sPLA2, a family of secreted phospholipases that are mediators in the inflammatory process involved in atherosclerosis, it hopes to create products that are either predictive of cardiovascular disease rather than simply diagnostic, or that can stop the development of unstable atherosclerotic plaques.
More from Archive
More from Scrip
• By
A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.
• By
The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.
• By
Comes Days After PDUFA Pushback For GSK's Blenrep.